Integrated analysis of efficacy and safety of palonosetron (PALO) 0.75 mg IV for preventing chemotherapy-induced nausea and vomiting (CINV) in anthracycline and cyclophosphamide (AC/EC) combination chemotherapy in Japan: PALO Japanese breast cancer cooperative study group.

被引：0
|
作者：
Suzuki, Y.
Tokuda, Y.
Inoue, K.
Aogi, K.
Saito, M.
Yanagita, Y.
机构：
[1] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[2] Saitama Canc Ctr, Saitama, Japan
[3] Natl Hosp Org, Shikoku Canc Ctr, Shikoku, Ehime, Japan
[4] Juntendo Univ, Sch Med, Tokyo 113, Japan
[5] Gunma Canc Ctr, Gunma, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：280S / 280S
页数：1
相关论文
共 35 条
  • [21] Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC).
    Karthaus, Meinolf
    Szabo, Peter
    Voisin, Daniel
    Rizzi, Giada
    Ciuleanu, Tudor
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [22] Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy
    Schilling, Joerg
    Kurbacher, Christian M.
    Hanusch, Claus
    Busch, Steffi
    Hollaender, Martin
    Kreiss-Sender, Janine
    Rezek, Daniela
    Flahaut, Elisa
    Karthaus, Meinolf
    BREAST CARE, 2022, 17 (02) : 130 - 136
  • [23] Efficacy of thalidomide, neurokinin-1 receptor antagonist, and olanzapine in combination with palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) induced by highly emetogenic chemotherapy (HEC): Bayesian network meta-analysis
    Alhifany, Abdullah
    McBride, Ali
    Almutairi, Abdulaali
    Babiker, Hani M.
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Efficacy of intravenous (IV) NEPA and oral NEPA, fixed NK1/5-HT3 receptor antagonist (RA) combination agents, for prevention of chemotherapy-induced nausea and vomiting (CINV) following anthracycline-cyclophosphamide (AC)-based chemotherapy
    Aapro, Matti
    Schwartzberg, Lee
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron)
    Jahn, P.
    Jordan, K.
    Rizzi, G.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S20 - S21
  • [26] Efficacy of ginger for chemotherapy-induced nausea and vomiting (CINV) prophylaxis in breast cancer patients receiving adriamycin - cyclophosphamide (AC) regimen: Randomized double-blind placebo control crossover study.
    Thamlikitkul, Lucksamon
    Soparattanapaisarn, Nopadol
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Evaluation of sustained antiemetic efficacy over repeated cycles of anthracycline-cyclophosphamide (AC)-based chemotherapy: A phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron for prevention of chemotherapy-induced nausea and
    Aapro, Matti
    Rugo, Hope
    Rizzi, Giada
    CANCER RESEARCH, 2015, 75
  • [28] Avoidable acute care involving chemotherapy-induced nausea and vomiting (CINV) among patients with breast cancer receiving anthracycline plus cyclophosphamide (AC) with NEPA prophylaxis relative to other antiemetics: An external control arm analysis
    Schwartzberg, Lee
    Ruddy, Kathryn J.
    Navari, Rudolph M.
    LeBlanc, Thomas W.
    Clark-Snow, Rebecca
    Wickham, Rita
    Binder, Gary
    Bailey, William L.
    Potluri, Ravi
    Schmerold, Luke M.
    Papademetriou, Eros
    Roeland, Eric J.
    CANCER RESEARCH, 2020, 80 (04)
  • [29] PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF SUSTAINED-RELEASE GRANISETRON (APF530) AND PALONOSETRON IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY
    Smith, Carrie
    Gabrail, Nashat
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E97 - E97
  • [30] Efficacy of single administration of oral NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving adjuvant AC-based chemotherapy - Results from GIM15-NEPA Study
    De laurentiis, M.
    Amaducci, L.
    Bilancia, D.
    Cassano, A.
    Cazzaniga, M. E.
    Cilenti, G.
    Fabi, A.
    Fava, S.
    Giordano, M.
    Guarneri, V.
    Molica, S.
    Montesarchio, V.
    Nicolini, M.
    Ricci, S.
    Schirone, A.
    Santoro, A.
    Scambia, G.
    Caputo, R.
    Bonizzoni, E. A.
    De Placido, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S53 - S54
1234